

# Islatravir Clinical Program Overview

*For Media Background*

June 2021



Islatravir (formerly MK-8591, EFdA) is Merck's investigational nucleoside reverse transcriptase translocation inhibitor. Islatravir is currently being evaluated for the treatment of HIV-1 infection in combination with other antiretrovirals, as well as for pre-exposure prophylaxis (PrEP) of HIV-1 infection as a single agent across a variety of formulations.

Islatravir remains under development and is not approved by regulatory authorities for use in any population. Additional information about the islatravir clinical development program can be found at [www.clinicaltrials.gov](http://www.clinicaltrials.gov).



\* collaboration with Gilead

\*\* collaboration with Bill & Melinda Gates Foundation for IMPOWER 22 clinical trial

		<b>Study Title</b>	<b>Study Description</b>	<b>Dosing</b>
<b>Phase 3</b>	<b>Treatment</b>	ILLUMINATE SWITCH A (MK-8591A-017, <a href="#">NCT04223778</a> ) <i>No longer recruiting</i>	Open-label switch from baseline antiretroviral therapy to oral DOR/ISL in adults with HIV-1	Once-daily
		ILLUMINATE SWITCH B (MK-8591A-018, <a href="#">NCT04223791</a> ) <i>No longer recruiting</i>	Blinded Switch from BIC/FTC/TAF to oral DOR/ISL in adults with HIV-1	Once-daily
		ILLUMINATE HTE (MK-8591A-019, <a href="#">NCT04233216</a> )	Oral DOR/ISL in heavily treatment-experienced participants with HIV-1	Once-daily
		ILLUMINATE NAÏVE (MK-8591A-020, <a href="#">NCT04233879</a> )	Oral DOR/ISL vs. BIC/FTC/TAF in treatment-naïve adults with HIV-1	Once-daily
	<b>PrEP</b>	IMPOWER 22 (MK-8591-022, <a href="#">NCT04644029</a> )	Oral ISL vs. once-daily FTC/TDF in cisgender women at high risk for HIV-1	Once-monthly
		IMPOWER 24 (MK-8591-024, <a href="#">NCT04652700</a> )	Oral ISL vs. once-daily FTC/TDF or FTC/TAF in men and transgender women who have sex with men, at high risk for HIV-1	Once-monthly
<b>Phase 2</b>	<b>Treatment</b>	MK-8591-011 ( <a href="#">NCT03272347</a> ) <i>No longer recruiting</i>	Dose-Ranging oral DOR+ISL in treatment-naïve adults with HIV-1	Once-daily
		ILLUMINATE ADOLESCENTS (MK-8591A-028, <a href="#">NCT04295772</a> )	Oral DOR/ISL in treatment experienced adolescents with HIV-1	Once-daily
		IMAGINE-DR (MK-8591-013, <a href="#">NCT04564547</a> )	Blinded switch from BIC/FTC/TAF to ISL and MK-8507 in virologically suppressed adults with HIV-1	Once-weekly
	<b>PrEP</b>	MK-8591-016 ( <a href="#">NCT04003103</a> ) <i>No longer recruiting</i>	Oral ISL in adults at low risk of HIV-1 infection	Once-monthly
<b>Phase 1</b>	<b>PrEP</b>	Long-acting subdermal implant of ISL in healthy adults <i>No longer recruiting</i>		
<b>Planned Studies</b>	<b>Treatment</b>	Long-acting oral and injectable formulations for islatravir + lenacapavir in collaboration with Gilead <i>These studies have not initiated yet</i>		